Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04541186 · ClinicalTrials.gov registry record · Phase 2
Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
A Phase 2 study, sponsored by 89bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT04541186 is a Phase 2 study that has completed, run by 89bio. The registered enrollment target is 86 participants.
The verdict
NCT04541186, a Phase 2 study, has completed, sponsored by 89bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (once weekly \[QW\] or every 2 weeks \[Q2W\]), subcutaneous (SC) dosing of BIO89-100 (pegozafermin) compared to placebo in participants with severe hypertriglyceridemia (SHTG).
Interventions
- DRUG Placebo
- DRUG Pegozafermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04541186
The ClinicalTrials.gov registry entry for NCT04541186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 89bio, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04541186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04541186 about?
NCT04541186 is a clinical study titled "Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia". This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (once weekly \[QW\] or every 2 weeks \[Q2W\]), subcutaneous (SC) dosing of BIO89-100 (pegozafermin) compared to placebo in participants with severe hypertriglyceridemia (SHTG).
What is the current status of trial NCT04541186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2020-09-01. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT04541186?
The interventions under investigation include: Placebo (DRUG), Pegozafermin (DRUG).
Who is sponsoring clinical trial NCT04541186?
This trial is sponsored by 89bio, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.